The economic impact of living with a rare disease for children and their families: a scoping review protocol
preprint
OA: closed
CC-BY-4.0
Abstract
Background: Rare diseases are an often chronic, progressive and life-limiting group of conditions affecting more than 30 million people in Europe. These diseases are associated with significant direct and indirect costs to a spectrum of stakeholders, ranging from individuals and their families to society overall. Further quantitative research on the economic cost for children and their families living with a rare disease is required as there is little known on this topic. This scoping review aims to document the extent and type of evidence on the economic impacts of living with a rare disease for children and their families. Methods This scoping review will follow the PRISMA-ScR and Joanna Briggs Institute guidelines and follow the six-stage methodology for scoping reviews: (1) identifying the research question, (2) identifying relevant studies, (3) study selection, (4) charting the data, (5) collating, summarising and reporting results and (6) knowledge user consultation. Key inclusion criteria have been developed according to the Population-Concept-Context (PCC) framework. The databases EconLit, ABI/Inform, MEDLINE, PubMed, CINAHL, and Scopus will be searched for possible articles for inclusion. Two independent reviewers will screen titles and abstracts of potential articles using a dual review process to ensure all relevant studies are included. All included articles will be assessed using a validated quality appraisal tool. A panel of patient and public involvement representatives experiencing rare diseases and knowledge users will validate the review results. Conclusions This scoping review will map the current literature on the economic impact of paediatric rare diseases to understand how these impacts affect children living with rare diseases and their families. This evidence has the potential to influence policy and future research in this area and will support further research on the economic impact of rare diseases on families.
My notes (saved in your browser only)
Funding
- funders
- [{'doi': '10.13039/501100001631', 'name': 'University College Dublin', 'awards': []}]
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (38)
- Rare Disease Research Partnership (RAinDRoP): a collaborative approach to identify research priorities for rare diseases in Ireland via crossref
- doi:10.1080/1364557032000119616 via crossref
- doi:10.1080/13645579.2021.1899596 via crossref
- doi:10.1007/s11606-020-05805-2 via crossref
- doi:10.1016/j.lanwpc.2023.100711 via crossref
- doi:10.1111/cts.12501 via crossref
- doi:10.3389/fphar.2022.914338 via crossref
- doi:10.1136/rmdopen-2020-001287 via crossref
- doi:10.1186/s13023-021-01815-3 via crossref
- doi:10.3390/ijerph191610366 via crossref
- doi:10.1136/emj.19.3.198 via crossref
- doi:10.1186/s12916-021-02204-0 via crossref
- doi:10.1186/1750-1172-8-135 via crossref
- doi:10.1016/j.jhealeco.2017.03.006 via crossref
- doi:10.3350/cmh.2014.20.4.327 via crossref
- doi:10.3389/fgene.2021.701988 via crossref
- doi:10.2165/11588380-000000000-00000 via crossref
- doi:10.1186/1748-5908-5-69 via crossref
- doi:10.2165/00019053-199813010-00001 via crossref
- doi:10.1007/s10198-016-0780-7 via crossref
- doi:10.1186/s13023-022-02550-z via crossref
- doi:10.1038/s41431-019-0508-0 via crossref
- doi:10.1136/bmj.n71 via crossref
- doi:10.1097/xeb.0000000000000050 via crossref
- doi:10.46658/jbimes-20-12 via crossref
- doi:10.11124/jbies-20-00167 via crossref
- doi:10.1177/1355819619841647 via crossref
- doi:10.11124/jbies-21-00416 via crossref
- doi:10.3310/nihropenres.1115214.1 via crossref
- doi:10.1186/s13023-016-0551-7 via crossref
- doi:10.1007/978-3-031-27496-1_7 via crossref
- doi:10.1016/j.pedn.2022.10.014 via crossref
- doi:10.11124/jbies-20-00361 via crossref
- doi:10.7326/m18-0850 via crossref
- doi:10.1038/s41434-019-0110-7 via crossref
- doi:10.1186/s13023-022-02299-5 via crossref
- doi:10.1016/j.healthpol.2014.12.016 via crossref
- doi:10.1136/adc.2007.134940 via crossref
Source provenance
- crossref
- last seen: 2026-07-06T06:39:09.018703+00:00
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00
- unpaywall
- last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0